DAS-181

Excerpt

A 64-year-old woman and a 69-year-old man, both with a history of stem cell transplantation, were hospitalised with paravirus infection and required mechanical ventilation. In both patients, Emergency Investigational New Drug permission for the use of DAS-181 was obtained, with a planned duration of 5 days. Both patients received nebulised DAS-181 3.2 mg/day for three days, followed by 4.5 mg/day for 2 days. Both patients experienced treatment-associated increases of their serum ALP levels, peaking at 240 mg/dL in the woman 6 days after DAS-181 initiation, and at 169 mg/dL in the man [time to reaction onset not stated; outcomes not stated]. …